Antithrombotic and fibrinolytic drugs for retinal vein occlusion: A systematic review and a call for action

Thrombosis and Haemostasis

Volumn 103, Issue 2, 2010, Pages 271-276

  Squizzato, Alessandro ^a   Manfredi, Elisa ^a   Bozzato, Silvia ^a   Dentali, Francesco ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Antithrombotic drugs; Low molecular weight heparin; Retinal vein occlusion; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; DICOUMAROL; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TICLOPIDINE; WARFARIN;

CLINICAL TRIAL; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DRUG DOSE COMPARISON; HEMODILUTION; HUMAN; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; RETINA VEIN OCCLUSION; REVIEW; SYSTEMATIC REVIEW; VEIN THROMBOSIS; VISUAL ACUITY;

ASPIRIN; DRUG EVALUATION; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL VEIN OCCLUSION; TICLOPIDINE; TREATMENT OUTCOME; VISUAL ACUITY; WARFARIN;

EID: 75749111693     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-09-0626     Document Type: Review

References (25)

1. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-143.
2. Hayreh SS, Zimmerman B, McCarthy MJ, et al. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
3. Koizumi H, Ferrara DC, Bruè C, et al. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; 144: 858-863.
4. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
5. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
6. Mohamed Q, McIntosh RL, Saw SM, et al. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 507-519.
7. McIntosh RL, Mohamed Q, Saw SM, et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 835-854.
8. Jadad AR, Moore AR, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 1-12.
9. Kohner EM, Hamilton AM, Bulpitt CJ, et al. Streptokinase in the treatment of central retinal vein occlusion. Trans Ophthal Soc UK 1974; 94: 599-603.
10. Kohner EM, Pettit JE, Hamilton AM, et al. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J 1976; 1: 550-553.
11. Houtsmuller AJ, Vermeulen JA, Klompe M, et al. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219-229.
12. Farahvash MS, Moghaddam MM, Moghimi S, et al. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol 2008; 43: 79-83.
13. Farahvash MS, Farahvash MM, Moradimogadam M, et al. Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. Arch Iran Med 2008; 11: 539-543.
14. Farahvash MS, Moradimogadam M, Farahvash MM, et al. Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 2008; 11: 418-422.
15. Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res 2009; Epub ahead of print.
16. Hattenbach LO, Friedrich AC, Lerche R, et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009; 29: 932-940.
17. Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 2008; 86: 245-252
18. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
19. Vannas S, Raitta C. Anticoagulant treatment of retinal venous occlusion. Am J Ophthalmol 1966; 62: 874-884.
20. Vannas S, Orma H. Experience of treating retinal venous occlusion with anticoagulant and antisclerosis therapy. AMA Arch Ophthalmol 1957; 58: 812-828.
21. Hecker SP, Zweng HC. Central retinal artery occlusion successfully treated with plasmin. J Am Med Assoc 1961; 176: 1067-1069.
22. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114: 79-102.
23. Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol 1997; 81: 698-704.
24. Sodi A, Giambene B, Marcucci R, et al. Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion.Eur J Ophthalmol 2008; 18: 233-238.
25. Sofi F, Marcucci R, Bolli P, et al. Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis 2008; 198: 223-227.